Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL596524 | 0.86 | SLC6A4 (0.40) | CA1CA2KDM4EATMSLC6A4 | |
| SCHEMBL10053287 | 0.85 | CA1 (0.44) | CA1CA2KDM4EATMSLC6A4 | |
| SCHEMBL597030 | 0.79 | CA1 (0.50) | CA1CA2 | |
| SCHEMBL595582 | 0.75 | SLC6A4 (0.37) | SLC6A4SLC6A2SLC6A3TAAR1 | |
| SCHEMBL10053200 | 0.73 | CA1 (0.43) | CA1CA2SLC6A4SLC6A2 | |
| SCHEMBL10053164 | 0.73 | CA1 (0.50) | CA1CA2ACHEALDH1A1TSHR | |
| SCHEMBL500078 | 0.69 | CA1 (0.53) | CA1CA2 | |
| SCHEMBL596466 | 0.68 | CA1 (0.41) | CA1CA2KDM4ESLC6A4LMNA | |
| SCHEMBL125255 | 0.66 | ALDH1A1 (0.57) | KDM4ESLC6A4SLC6A2LMNASLC6A3 | |
| SCHEMBL29729780 | 0.66 | ALDH1A1 (0.57) | KDM4ESLC6A4SLC6A2LMNASLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170066787-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. | 2017-03-09 | — | — | US | disclosed |
| US-9572823-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-9566290-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-9566289-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-9549938-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-20160228463-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. | 2016-08-11 | — | — | US | disclosed |
| US-20160206638-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. | 2016-07-21 | — | — | US | disclosed |
| US-20160184334-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. | 2016-06-30 | — | — | US | disclosed |
| US-20160151399-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. | 2016-06-02 | — | — | US | disclosed |
| US-9353133-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-7465836-B2 | Hydrolytically-resistant boron-containing therapeutics and methods of use | ANACOR PHARMACEUTICALS, INC. (US) | 2008-12-16 | — | — | US | disclosed |
| US-7465836-B2 | Hydrolytically-resistant boron-containing therapeutics and methods of use | ANACOR PHARMACEUTICALS, INC. (US) | 2008-12-16 | — | — | US | disclosed |
| EP-1976536-A2 | BORON-CONTAINING SMALL MOLECULES | Anacor Pharmaceuticals, Inc. (US) | 2008-10-08 | — | — | EP | disclosed |
| US-20070286822-A1 | Compounds for the Treatment of Periodontal Disease | ANACOR PHARMACEUTICALS INC. (US) | 2007-12-13 | — | — | US | disclosed |
| WO-2007078340-A2 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2007-07-12 | — | — | WO | disclosed |
| US-20070155699-A1 | Boron-containing small molecules | ANACOR PHARMACEUTICALS (US) | 2007-07-05 | — | — | US | disclosed |
| EP-1638578-A2 | HYDROLYTICALLY-RESISTANT BORON-CONTAINING THERAPEUTICS AND METHODS OF USE | Anacor Pharmaceuticals, Inc. (US) | 2006-03-29 | — | — | EP | disclosed |
| WO-2005013892-A9 | HYDROLYTICALLY-RESISTANT BORON-CONTAINING THERAPEUTICS AND METHODS OF USE | ANACOR PHARMACEUTICALS INC (US) | 2005-04-14 | — | — | WO | disclosed |
| US-20050054644-A1 | Hydrolytically-resistant boron-containing therapeutics and methods of use | ANACOR PHARMACEUTICALS, LLC | 2005-03-10 | — | — | US | disclosed |
| WO-2005013892-A2 | HYDROLYTICALLY-RESISTANT BORON-CONTAINING THERAPEUTICS AND METHODS OF USE | ANACOR PHARMACEUTICALS, INC. (US) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160206638-A1 | BORON-CONTAINING SMALL MOLECULES | ETF1, POLR1C, DPM1 | CA1 4091/4885CA2 1368/4885KDM4E 3418/4885 |
| US-20170066787-A1 | BORON-CONTAINING SMALL MOLECULES | ETF1, POLR1C, DPM1 | CA1 4091/4885CA2 1368/4885KDM4E 3418/4885 |
| US-20160151399-A1 | BORON-CONTAINING SMALL MOLECULES | ETF1, POLR1C, DPM1 | CA1 4091/4885CA2 1368/4885KDM4E 3418/4885 |
| US-20160228463-A1 | BORON-CONTAINING SMALL MOLECULES | ETF1, POLR1C, DPM1 | CA1 4091/4885CA2 1368/4885KDM4E 3418/4885 |
| US-20070286822-A1 | Compounds for the Treatment of Periodontal Disease | BPGM, HMBS, PPIP5K2 | CA1 3204/4885CA2 1752/4885KDM4E 3530/4885 |
| US-20070155699-A1 | Boron-containing small molecules | ETF1, POLR1C, DPM1 | CA1 4091/4885CA2 1368/4885KDM4E 3418/4885 |
| US-20160184334-A1 | BORON-CONTAINING SMALL MOLECULES | ETF1, POLR1C, DPM1 | CA1 4091/4885CA2 1368/4885KDM4E 3418/4885 |
| US-20050054644-A1 | Hydrolytically-resistant boron-containing therapeutics and methods of use | BTD, GAA, GBA3 | CA1 897/4885CA2 491/4885KDM4E 2666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.